维普中文期刊产品整合服务
46篇 您的检索式:作者名="VOSWINCKEL R"
    题名 作者 年代 出处 被引量
1Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies 显示文摘Voswinckel R Enke B Reichenberger F 2006J Am Coll Cardiol2006,48,8:1
2Complications of rightheart catheterization procedures in patients with pulmonary hyper-tension in experienced centers显示文摘Hoeper MM Lee SH Voswinckel R 2006Am Coll Cardiol2006,48,:1
3Evidence of dysfunction of endothelial progenitors in pulmonary arte- rial hypertension显示文摘Toshner M Voswinckel R Southwood M 2009Am J Respir Crit Care Med2009,180,8:1
4The protein tyrosine kinase inhibitor SU5614 inhibits VEGF2 induced endothelial cells sprouting and induces growth arrest and apoptosis by inhibition of AML cells显示文摘Spiekermarn K Faber F Voswinckel R 2002Exp Hematol2002,30,7:1
5Lung endothelial monocyte-activating protein 2 is a mediator ofcigarette smoke-induced emphysema in mice显示文摘Clauss M Voswinckel R Rajashekhar G 0,,:1
6Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension显示文摘Toshner M Voswinckel R Southwood M 2009Am J Respir Crit Care Med2009,180,8:1
7Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension显示文摘VOSWINCKEL R REICHENBERGER F ENKE B et ol 2008Pulm Pharmacol Ther2008,21,5:1
8Complications of Right Heart Catheterization Procedures in Patients with Pulmonary Hypertension显示文摘Hoeper MM Lee SH Voswinckel R Journal of the American College of Cardiology0,,:1
9Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension 显示文摘Voswinckel R Reichenberger F Gall H 2009Pulm Pharmacol Ther2009,22,1:1
10Emerging therapies for the treatment of pulmonary arterial hypertension显示文摘GHOFRANI HA VOSWINCKEL R REICHENBERGER H 2005Herz2005,30,4:1
11The protein tyrosine kinase inhibitor SU5614 inhibits VEGF- induced endothelial cells sprouting and induces growth arrest and apoptosis by inhibition of ckitin AME cells 显示文摘Spiekermann K Faber F Voswinckel R 2002Exp Hematol2002,30,:1
12Participation of bone marrow-derived cells in long term repair processes following experimental stroke显示文摘Beck H Voswinckel R Wagner S 2003J Cereb Blood Flow Metab2003,23,:1
13Hypoxia and non-hypoxia-related pulmonary hypertention established and new therapies显示文摘Ghofrani H A Voswinckel R Reichenberger F 2006Cardiovasc Res2006,72,:1
14Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension:a randomized prospective study显示文摘Ghofrani HA Voswinckel R Reichenberger F 2004J Am Coll Cardiol2004,44,7:1
15Senescence - associated secreto- ry phenotype and its possible role in chronic obstructive pulmonary disease 显示文摘Kumar M Seeger W Voswinckel R 2014Am J Respir Cell Mol Biol2014,51,3:1
16Therapy of pulmona-ry arterial hypertension显示文摘Voswinckel R Reichenberger F Gall H 2009Internist(Berl)20092009,,:1
17Long-term open label treatment with inhaled treprostinil for pulmonaryarterial hypertension 显示文摘VOSWINCKEL R VAN DIJK A EDELMANN R 2009Am J Respir Crit Care Med2009,179,:1
18Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension显示文摘Pullamsetti S Kiss L Ghofrani HA Voswinckel R Haredza P Klepetko W 2005FASEB J2005,19,9:1
19Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension显示文摘Reichenberger F Voswinckel R Enke B 2007Eur Respir J2007,30,5:1
20The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c kit in AML cells 显示文摘Spiekermann K Faber F Voswinckel R 2002Exp Hematol2002,30,7:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费